• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Fennec Pharmaceuticals Inc.

    11/18/25 4:12:48 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $FENC alert in real time by email
    S-8 1 tm2530718d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on November 18, 2025

     

    Registration No. 333-

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    FENNEC PHARMACEUTICALS INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    British Columbia, Canada   20-0442384

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

     

    PO Box 13628, 68 TW Alexander Drive

    Research Triangle Park, NC 27709

    (Address of Principal Executive Offices) (Zip Code)

     

    Fennec Pharmaceuticals Inc. 2020 Equity Incentive Plan

    (Full Title of the Plans)

     

    Jeff Hackman

    Chief Executive Officer

    PO Box 13628, 68 TW Alexander Drive

    Research Triangle Park, NC 27709

    (Name and Address of Agent for Service)

     

    (919) 636-4530

    (Telephone Number, including Area Code, of Agent for Service)

     

    Copies to:

     

    Garett Sleichter, Esq. Randy Taylor, Esq.
    Rutan & Tucker, LLP LaBarge Weinstein LLP
    18575 Jamboree Road, 9th Floor 515 Legget Drive, Suite 800
    Irvine, CA 92612 Ottawa, ON K2K 3G4
    (714) 641-5100 (613) 599-9600

      

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
           
    Non-accelerated filer x Smaller reporting company x
           
        Emerging growth company ¨

     

     If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

      

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information.*

     

    Item 2. Registrant Information and Employee Plan Annual Information.*

     

    *The documents containing the information specified in this Part I will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act. These documents and the documents incorporated by reference in the registrant statement pursuant to Item 3 of Part II of this Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, which Fennec Pharmaceuticals Inc. (the “Company”, the “Registrant”, “Fennec”, “we”, “us” or “our”) has filed with the Commission are incorporated herein by reference:

     

    1. our Annual Report on Form 10-K for the year ended December 31, 2024 (the “Form 10-K”), filed with the Commission on March 26, 2025;

     

    2. the information specifically incorporated by reference into our Form 10-K from our Definitive Proxy Statement on Schedule 14A, filed with the Comission on April 25, 2025;

     

    3. our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025, and September 30, 2025, filed with the Commission on May 14, 2025, August 14, 2025, and November 13, 2025, respectively;

     

    4. our Current Reports on Form 8-K filed with the Commission on February 7, 2025, March 10, 2025, June 3, 2025, and November 18, 2025 only to the extent filed and not furnished; and

     

    5. the description of our capital stock contained in our Registration Statement on Form 8-A filed with the Commission on September 11, 2017, including any amendment or report filed with the Commission for the purpose of updating such description.

     

    In addition, all documents that we may file in the future pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold will be deemed to be incorporated by reference in this Registration Statement. We will deem all of these documents to be a part of this Registration Statement from the respective dates of filing these documents.

     

    We further regard any statement contained in a document that is incorporated by reference in this Registration Statement to be modified or superseded if this Registration Statement, or some other subsequently filed document that is also incorporated by reference in this Registration Statement, modifies or supersedes the statement. If this occurs, we regard the statement to be incorporated in this Registration Statement by reference only in the statement’s modified or superseded form.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

     

     

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Business Corporations Act (British Columbia)

     

    Division 5 of Part 5 of the Business Corporations Act (British Columbia) provides that a corporation may (a) indemnify an eligible party against all eligible penalties to which the eligible party is or may be liable and (b) after the final disposition of an eligible proceeding, pay the expenses (not including judgments, penalties, fines or amounts paid in settlement of a proceeding) actually and reasonably incurred by an eligible party in respect of that proceeding.

     

    An “eligible party” means an individual who (a) is or was a director or officer of the corporation, (b) is or was a director or officer of another corporation (i) at a time when the other corporation is or was an affiliate of the corporation, or (ii) at the request of the corporation, or (c) at the request of the corporation, is or was, or holds or held a position equivalent to that of, a director or officer of a partnership, trust, joint venture or other unincorporated entity.

     

    An “eligible proceeding” means a proceeding in which an eligible party or any of the heirs and personal or other legal representatives of the eligible party, by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, the corporation or an associated corporation (a) is or may be joined as a party, or (b) is or may be liable for or in respect of a judgment, penalty or fine in, or expenses related to, the proceeding.

     

    A corporation must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by the eligible party in respect of that proceeding if the eligible party (a) has not been reimbursed for those expenses, and (b) is wholly successful, on the merits or otherwise, in the outcome of the proceeding or is substantially successful on the merits in the outcome of the proceeding.

     

    A corporation may pay, as they are incurred in advance of the final disposition of an eligible proceeding, the expenses actually and reasonably incurred by an eligible party in respect of that proceeding, provided the corporation first receives from the eligible party a written undertaking that, if it is ultimately determined that the payment of expenses is prohibited, the eligible party will repay the amounts advanced.

     

    Notwithstanding any of the foregoing, a corporation must not indemnify an eligible party or pay the expenses of an eligible party if any of the following circumstances apply:

     

      · if the indemnity or payment is made under an earlier agreement to indemnify or pay expenses and, at the time that the agreement to indemnify or pay expenses was made, the corporation was prohibited from giving the indemnity or paying the expenses by its memorandum or articles;

     

      · if the indemnity or payment is made otherwise than under an earlier agreement to indemnify or pay expenses and, at the time that the indemnity or payment is made, the corporation is prohibited from giving the indemnity or paying the expenses by its memorandum or articles;

     

      · if, in relation to the subject matter of the eligible proceeding, the eligible party did not act honestly and in good faith with a view to the best interests of the corporation or the associated corporation, as the case may be;

     

      · in the case of an eligible proceeding other than a civil proceeding, if the eligible party did not have reasonable grounds for believing that the eligible party’s conduct in respect of which the proceeding was brought was lawful.

     

    If an eligible proceeding is brought against an eligible party by or on behalf of the corporation or by or on behalf of an associated corporation, the corporation must not (a) indemnify the eligible party in respect of the proceeding or (b) pay the expenses of the eligible party in respect of the proceeding.

     

     

     

     

    A corporation may purchase and maintain insurance for the benefit of an eligible party or the heirs and personal or other legal representatives of the eligible party against any liability that may be incurred by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, the corporation or an associated corporation.

     

    Articles

     

    Our Articles provide that, subject to the Business Corporations Act (British Columbia), the Company must indemnify an eligible party and their respective heirs and personal or other legal representatives against all eligible penalties to which such eligible party is or may be liable. The Company must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by such person in respect of that proceeding. Each eligible party is deemed to have contracted with the Company on this term. The Articles also provide that the Company may indemnify any person, subject to any restrictions in the Business Corporations Act (British Columbia).

     

    Our Articles defines the following terms: (1) an “eligible penalty” means a judgment, penalty or fine awarded or imposed in, or an amount paid in settlement of, an “eligible proceeding”; (2) an “eligible party” means a director, former director or alternate director of the Company; (3) an “eligible proceeding” means a legal proceeding or investigative action (whether current, threatened, pending or completed), in which an eligible party or any of the heirs and personal or other legal representatives of the eligible party, by reason of the eligible party being or having been a director or alternate director of the Company (a) is or may be joined as a party, or (b) is or may be liable for or in respect of a judgment, penalty or fine in, or expenses related to, the proceeding; and (4) “expenses” has the meaning set out in the Business Corporations Act (British Columbia).

     

    Our Articles provide that the Company may purchase and maintain insurance for the benefit of any person (or his or her heirs or legal personal representatives) who is or was a director, alternative director, officer, employee or agent, or held or holds such position or a position equivalent to the foregoing (each, an “insured party”) with respect to (i) the Company; (ii) a corporation at a time when the corporation was an affiliate of the Company; (iii) at the request of the Company, served in such capacity with respect to a corporation, partnership, trust, joint venture or other unincorporated entity, against any liability that may be incurred by him or her acting in such capacity.

     

    We maintain liability insurance policies regarding our directors and officers against certain liabilities that they may incur in such capacities.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

     

    Item 7. Exemption From Registration Claimed.

     

    Not applicable.

     

     

     

      

    Item 8. Exhibits.

     

    Exhibit No.   Description of Exhibit
    4.1   Notice of Articles dated August 25, 2011 (incorporated herein by reference to Exhibit 3.2(i) to our Form 8-K filed August 26, 2011).
    4.2   Articles dated August 25, 2011 (incorporated herein by reference to Exhibit 3.2(ii) to our Form 8-K filed August 26, 2011).
    4.3   Notice of Alteration dated September 3, 2014 (incorporated herein by reference to Exhibit 3.1 to our Form 8-K filed September 9, 2014).
    4.4   Shareholder Rights Plan Agreement dated June 27, 2017 between Fennec Pharmaceuticals Inc. and Computershare Trust Company of Canada (incorporated herein by reference to Schedule B to our Management Proxy Circular filed May 24, 2017).
    4.5   Fennec Pharmaceuticals Inc. 2020 Equity Incentive Plan (incorporated herein by reference to Schedule B to our Management Proxy Circular filed April 25, 2025).
    5.1   Opinion of Counsel
    23.1   Consent of Counsel (included in Exhibit 5.1)
    23.2   Consent of Independent Registered Public Accounting Firm
    24.1   Power of Attorney (included in the Signature Page hereto)
    107   Filing Fee Table 

     

    Item 9. Undertakings.

     

    The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement; and

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided however, that paragraphs (i) and (ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Research Triangle Park, State of North Carolina on November 18, 2025.

     

    Fennec Pharmaceuticals Inc.

     
         
    By: /s/ Jeffrey Hackman  
      Jeffrey Hackman  
      Chief Executive Officer  

     

    POWER OF ATTORNEY

     

    We, the undersigned directors and officers of the Registrant, hereby severally constitute and appoint Jeff Hackman and Robert Andrade as our true and lawful attorneys, with full power to them to sign for us and in our names in the capacities indicated below, the Registration Statement on Form S-8 filed herewith, and any and all amendments (including post-effective amendments) to said Registration Statement, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of them might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this power of attorney. This power of attorney does not revoke any power of attorney previously granted by the undersigned, or any of them.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities indicated on the date indicated:

     

    Signature   Title   Date
             
    /s/  Jeffrey Hackman   Chief Executive Officer and Director   November 18, 2025
     Jeffrey Hackman   (principal executive officer)    
             
    /s/ Robert Andrade   Chief Financial Officer   November 18, 2025
    Robert Andrade   (principal financial and accounting officer)    
             
    /s/ Dr. Khalid Islam   Director   November 18, 2025
    Dr. Khalid Islam        
             
    /s/  Chris A. Rallis   Director   November 18, 2025
     Chris A. Rallis        
             
    /s/ Marco Brughera   Director   November 18, 2025
    Marco Brughera        
             
    /s/ Rostislav Raykov   Director   November 18, 2025
    Rostislav Raykov        
             
    /s/ Jodi Cook   Director   November 18, 2025
    Jodi Cook        

     

     

     

     

    Get the next $FENC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FENC

    DatePrice TargetRatingAnalyst
    11/22/2022$9.00 → $12.00Neutral → Overweight
    Cantor Fitzgerald
    9/7/2022$11.00Overweight
    CapitalOne
    8/8/2022$14.00Buy
    Craig Hallum
    More analyst ratings

    $FENC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption

    RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced it has repurchased and redeemed all of Fennec's outstanding convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP using proceeds from the closing of the Company's previously announced underwritten public offering in the United States and concurrent private placement in Canada, closed on November 17 and 18, 2025, respectively. The Company has no outstanding debt after the redemption of Petrichor's convertible notes. The aggregate repurch

    11/19/25 7:03:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada

    RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced the closing of its non-brokered offering of its common shares in Canada, at a price of US$7.50 per share, with certain of its existing institutional shareholders, for aggregate gross proceeds of US$5,025,000. The offering was made to prospective purchasers resident in any province in Canada (except Quebec) pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions and the Company has registered the common shares issued in the offering un

    11/18/25 8:30:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals Announces Closing of Offering of Common Shares

    RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) ("Fennec" or the "Company"), a specialty pharmaceutical company, today announced the closing of its underwritten registered public offering of 5,366,667 common shares (which amount includes exercise in full of the underwriters' option to purchase additional common shares) at a public offering price of $7.50 per share. Fennec's total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) are approximately $40,250,000. Fennec intends to use the net proceeds of the offering to repurchase and redeem certain indebtedness and the remai

    11/17/25 4:15:00 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Southpoint Capital Advisors Lp sold $170,048 worth of shares (19,341 units at $8.79) (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    11/20/25 4:07:55 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Southpoint Capital Advisors Lp sold $2,035,625 worth of shares (246,018 units at $8.27) (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    11/17/25 8:42:18 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Raykov Rosty sold $81,000 worth of shares (10,000 units at $8.10), decreasing direct ownership by 11% to 82,318 units (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    11/6/25 4:10:28 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Hackman Jeffrey S. bought $104,602 worth of shares (15,000 units at $6.97) (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    5/19/25 5:42:21 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Andrade Robert bought 12,500 shares, increasing direct ownership by 14% to 104,271 units (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    4/3/24 5:00:11 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raykov Rosty bought 29,167 shares, increasing direct ownership by 10% to 316,638 units (SEC Form 4)

    4 - FENNEC PHARMACEUTICALS INC. (0001211583) (Issuer)

    4/3/24 4:55:10 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fennec Pharmaceuticals upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Fennec Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously

    11/22/22 9:21:25 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CapitalOne initiated coverage on Fennec Pharmaceuticals with a new price target

    CapitalOne initiated coverage of Fennec Pharmaceuticals with a rating of Overweight and set a new price target of $11.00

    9/7/22 8:58:27 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Craig Hallum resumed coverage on Fennec Pharmaceuticals with a new price target

    Craig Hallum resumed coverage of Fennec Pharmaceuticals with a rating of Buy and set a new price target of $14.00

    8/8/22 8:53:55 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PEDMARK issued to FENNEC PHARMACEUTICALS INC

    Submission status for FENNEC PHARMACEUTICALS INC's drug PEDMARK (ORIG-1) with active ingredient SODIUM THIOSULFATE has changed to 'Approval' on 09/20/2022. Application Category: NDA, Application Number: 212937, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/20/22 3:54:04 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    SEC Filings

    View All

    Fennec Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

    11/19/25 7:10:41 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Fennec Pharmaceuticals Inc.

    S-8 - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

    11/18/25 4:12:48 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)

    11/18/25 4:05:38 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Leadership Updates

    Live Leadership Updates

    View All

    Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

    ~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr. Jeff Hackman as its Chief Executive Officer (CEO) and a member of the Board of Directors, effective on or about August 16, 2024. Jeff will guide Fennec's strategic direction for operational success in the expansion of PEDMARK® use in c

    8/5/24 6:26:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Fennec Pharmaceuticals Inc.

    SC 13G/A - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

    11/12/24 7:38:18 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Fennec Pharmaceuticals Inc.

    SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

    6/27/24 4:43:33 PM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Fennec Pharmaceuticals Inc.

    SC 13G - FENNEC PHARMACEUTICALS INC. (0001211583) (Subject)

    2/14/24 10:47:17 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FENC
    Financials

    Live finance-specific insights

    View All

    Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update

    ~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community Practices and Academic Centers, Supported by Targeted Sales Strategy and Enhanced Patient Support Services for PEDMARK® ~ ~ Successful Initial Uptake of PEDMARQSI® in the United Kingdom and Germany with Additional EU Launches Planned ~ ~ Japan Clinical Trial (STS-J01) Results Expected in the Second Half of 2025 with Evaluation of Both Registration and Partnering or Licensing Expected Thereafter ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.

    8/14/25 6:08:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025

    RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, August 14, 2025. Management will host a conference call and webcast that day to discuss the Company's financial and business results. Conference Call & Webcast Detail: Date: Thursday, August 14, 2025Time: 8:30 a.m. Eastern TimeWebcast Link: https://edge.media-server.com/mmc/p/de4jxxzj   Participant Link: https://register-conf.media-server.com/register/BI3e750b95d06c439ea560b

    8/11/25 7:12:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

    ~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company's Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~ ~ PEDMARQSI Now Commercially Available in Germany and the United Kingdom ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., May 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a specialty pharmaceutical company, today reported its financial results for the first quarter ended March 31, 2025 and provided a business update. "In the first quarter, we sharpened our strategic focus and achieved sustainable gro

    5/13/25 6:03:00 AM ET
    $FENC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care